At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 370 enrolled
Drug / intervention
225 mg BNC210 +1 moredrug
Likely dose
225 mg BNC210from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder
In Brief
A Phase 3 clinical trial evaluating 225 mg BNC210 and Placebo for Social Anxiety Disorder. Completed, enrolled 370 participants across 21 sites.
Detailed Summary
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSocial Anxiety Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
First PostedJul 2024
Enrollment StartAug 2024
Primary CompletionSep 2025
Study CompletionSep 2025
TodayJul 2026
First PostedJul 19, 2024
Enrollment StartAug 6, 2024
Primary CompletionSep 11, 2025
Study CompletionSep 19, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.0 years ago
Interventions
225 mg BNC210drug
225 mg BNC210
Placebodrug
Placebo